Search Bar & Filters
Found 11 Actively Recruiting clinical trials
Actively Recruiting
Healthy Volunteer
This research aims to evaluate whether creating dedicated HIV teams in hospitals across ten European countries can increase HIV testing rates among patients showing signs of HIV-related conditions. The study uses a stepped-wedge design, where hospitals switch from routine care to the new intervention in sequence. This approach compares outcomes before and after the teams are in place, helping to understand the impact of the intervention across various locations and medical specialties. The intervention involves establishing local HIV teams led by specialists and supported by nurses and data experts. These teams identify patients needing HIV tests through electronic health records, provide feedback to doctors to encourage testing, offer education to healthcare staff about HIV, reduce stigma, and improve connections to prevention and care services. This program integrates smoothly into regular hospital routines and aims to close gaps in HIV diagnosis. Participants HIV testing rates will be monitored by reviewing records before and after the intervention. Researchers will also assess new HIV diagnoses, changes in testing patterns by country and specialty, and healthcare professionals knowledge and attitudes toward HIV. The study includes ongoing evaluation of how well the teams operate, resource use, and cost-effectiveness. Data collection extends up to several years to observe long-term effects, with continuous monitoring of care access and prevention services.
Actively Recruiting
Researchers are evaluating treatments for germinal center B-cell-like diffuse large B-cell lymphoma GCB DLBCL, a fast-growing blood cancer affecting immature B-cells. The study aims to determine if more people respond to zilovertamab vedotin MK-2140 combined with R-CHP compared to polatuzumab vedotin combined with R-CHP. This is a phase 2 randomized study focused on participants who have not been treated before and have the GCB subtype of DLBCL. Participants will be randomly assigned to receive either zilovertamab vedotin plus cyclophosphamide, doxorubicin, rituximab or its biosimilar R-CHP, or polatuzumab vedotin plus R-CHP. These drugs are given by intravenous infusion on Day 1 of each 3-week cycle for up to 6 cycles, about 4 months. Additionally, participants take prednisone or prednisolone tablets daily on Days 1 to 5 of each cycle. Those with high-risk DLBCL may receive 2 extra cycles of rituximab or its biosimilar. Throughout the study, participants undergo assessments including PET scans to monitor cancer response, and various health evaluations. Researchers measure complete response rate at the end of treatment, progression-free survival, overall survival, event-free survival, and quality of life using standardized tools. Safety is monitored by tracking adverse events and treatment tolerability. The study lasts up to several years with follow-up for long-term outcomes.
Actively Recruiting
Researchers are conducting a multi-centre observational study to better understand giant cell arteritis GCA and polymyalgia rheumatica PMR, conditions mainly affecting people over 50 years old. The study aims to identify genetic factors that influence susceptibility to these diseases to provide new insights into how they develop. It includes both retrospective participants with confirmed diagnoses and prospective participants suspected of having these conditions, with some patients also enrolled in a registry monitoring tocilizumab treatment for relapsing or refractory GCA. The study collects detailed clinical, imaging, and molecular data, including genetic and proteomic analyses, from participants to characterize disease subtypes and impacts. Researchers also assess quality of life through patient-reported outcomes and track long-term prognosis by linking to health records. The study explores environmental factors and co-existing conditions to improve diagnosis, prognosis, and monitoring of disease activity, especially for patients receiving synthetic or biological disease-modifying anti-rheumatic drugs. Participants provide information during baseline assessments, including blood and urine samples for analysis, and complete questionnaires about their symptoms and quality of life. Follow-up occurs through health record review over an average of one year to evaluate diagnosis and disease outcomes. The primary measure is genetic susceptibility, with secondary outcomes focusing on disease characteristics, life impact, diagnosis, and disease activity. The study is sponsored by the University of Leeds and started in 2005, continuing through 2028.
Actively Recruiting
Researchers are investigating whether adding duroplasty, a surgical procedure that expands the tough membrane around the spinal cord, improves outcomes after severe cervical spinal cord injury. This trial focuses on adults with acute, severe injuries in the neck area who require surgery within 72 hours. The study aims to determine if duroplasty combined with standard bony decompression surgery enhances muscle strength and functional recovery compared to bony decompression alone. Participants will be randomly assigned to receive either standard spinal surgery including laminectomy alone or the same surgery plus duroplasty. Some patients may also join an optional mechanistic sub-study where probes and microdialysis catheters monitor spinal cord pressure, blood flow, metabolism, and inflammation at the injury site. The study will recruit around 222 to 260 patients over four years, including sites in the UK and internationally. During the study, participants will be assessed at baseline, 3, 6, and 12 months after surgery using questionnaires and physical examinations to measure muscle strength, hand function, walking ability, bladder and bowel control, and quality of life. Some will have MRI scans at 2 weeks and 6 months, and safety outcomes such as complications, additional surgeries, and mortality will be tracked up to 12 months. Follow-up lasts one year to evaluate recovery and treatment impact.
Actively Recruiting
Researchers are evaluating the Heartfelt device, a new passive monitoring system that detects early signs of fluid build-up in patients with heart failure by measuring changes in foot and lower leg volume using 3D images. The study aims to see if adding this device to standard NHS care improves quality of life and reduces heart failure-related events compared to standard care alone. The trial involves 300 participants from multiple NHS hospitals and GP practices across the UK and uses a randomized crossover design. Participants will be randomly assigned to receive either standard NHS care, which includes regular weight checks and symptom monitoring, or standard care plus the Heartfelt device installed at home. The device captures daily images of the feet to track swelling without extra effort from the user. Alerts triggered by important changes are sent to the clinical team for prompt action. Both groups receive a patient booklet from the British Heart Foundation to support self-monitoring and understanding of heart failure. During the study, participants quality of life will be assessed using questionnaires at baseline and at 3, 6, 9, and 12 months. The study will also monitor hospitalizations, deaths, medication adherence, and the availability of daily device data. Researchers will evaluate how the clinical teams respond to alerts, the ease of device use, and its cost-effectiveness. The total participation period covers 12 months of monitoring and data collection.
Actively Recruiting
Researchers are conducting an observational study to describe the characteristics and real-world clinical outcomes of patients with chronic lymphocytic leukemia CLL who received acalabrutinib in the United Kingdom through the Early Access Programme EAP. The study aims to estimate progression-free survival, overall survival, response rates, healthcare resource use, and treatment patterns in these patients. Participants in this study are patients who started first-line treatment with acalabrutinib between April 1, 2020, and April 1, 2021, as part of the UK EAP. The study is non-interventional, meaning no study drug is administered by researchers instead, data are collected retrospectively from patients clinical records according to local laws. During the study, researchers will review clinical data from patient records to measure outcomes such as progression-free survival at multiple time points up to 60 months, overall survival, response rates, and treatment interruptions. The study will provide real-world evidence on acalabrutinib use and outcomes in CLL patients over an average of five years, with no additional treatments or visits required from participants.
Actively Recruiting
Researchers are studying patients with newly diagnosed stage I, II, and III colorectal cancer CRC to understand how circulating tumor DNA ctDNA in the blood can predict disease relapse. The study evaluates whether using ctDNA to guide adjuvant chemotherapy decisions after surgery is as effective as standard chemotherapy, aiming to reduce unnecessary treatments and side effects. This multi-center, prospective research includes both observational and randomized components to better manage early-stage CRC. The study has two parts Part B focuses on collecting tumor tissue, serial blood samples, and clinical data to detect minimal residual disease MRD using ctDNA after curative surgery. Part C is a randomized trial comparing ctDNA-guided adjuvant chemotherapy versus standard care in patients with high-risk stage II or III CRC. Patients are randomized post-surgery to either standard chemotherapy or a ctDNA-guided approach where those testing negative for ctDNA may receive less chemotherapy. Participants will undergo regular blood sampling and clinical assessments to monitor ctDNA levels and disease status. Researchers will measure outcomes such as 3-year disease-free survival and the relationship between ctDNA detection and treatment response over several years. The study includes follow-up periods of 4 to 8 years to evaluate long-term outcomes and safety. Participants need to consent, adhere to follow-up schedules, and be suitable for chemotherapy if randomized to Part C.
Actively Recruiting
Rhegmatogenous retinal detachment RRD is a serious condition where the retina detaches from the back of the eye, leading to vision loss and requiring surgery. This trial studies adults aged 50 and older with non-highly myopic RRD who have not had previous vitreoretinal surgery. It compares two surgical approaches vitrectomy alone versus vitrectomy combined with cataract surgery in one procedure. The study aims to determine which method results in better vision recovery, fewer complications, and improved patient satisfaction. Participants will be randomly assigned to one of two groups. One group will receive vitrectomy alone to repair the retinal detachment, and cataract surgery will be performed later if needed. The other group will undergo phacovitrectomy, which combines vitrectomy with cataract removal and intraocular lens implantation in the same surgery. Surgeons will follow specific protocols for lens selection, especially when the central retina is detached. The choice of surgical tools and additional treatment agents will be based on standard care practices at each site. Throughout the study, participants will be monitored for up to 52 weeks after surgery. Researchers will measure vision outcomes using best-corrected visual acuity, success rates of retinal reattachment, complication rates, and quality of life related to vision and health. Patient experience and treatment acceptability will be assessed through interviews and questionnaires. The study also evaluates healthcare usage, costs to participants, and safety. Data will help guide future surgical approaches for RRD.
Actively Recruiting
Heart failure with preserved ejection fraction HFpEF occurs when the hearts pumping function is normal but the heart cannot pump blood properly. This condition causes symptoms like breathlessness, swollen feet and ankles, and tiredness. HFpEF is complex and varies widely among patients, making it poorly understood with limited treatment options. The UK HFpEF study aims to improve understanding of why people develop HFpEF, create better diagnostic tests, identify new treatments, and follow participants health over many years. This observational study involves creating a large registry by collaborating across many centers in the UK. The registry will collect detailed information from thousands of patients with HFpEF, enabling researchers to classify the condition more precisely and develop personalized treatment approaches. This platform will support future research trials targeting specific patient groups and enable efficient patient recruitment. Participants will undergo detailed assessments including clinical evaluations, measurements of natriuretic peptide levels, and long-term health monitoring. Researchers will analyze data to identify distinct HFpEF subgroups, understand causes, and improve risk prediction over a 10-year period. This study is designed to provide important insights for better care and treatment strategies, with ongoing follow-up to track health outcomes.
Actively Recruiting
This research aims to compare two standard care approaches in very premature infants born before 30 weeks to see if withholding enteral feeds around the time of blood transfusion reduces the risk of Necrotizing Enterocolitis NEC, a serious intestinal disease. NEC can severely damage the bowel and has a high risk of death or long-term health problems. The study involves infants from neonatal intensive care units in Canada and the UK and evaluates if withholding or continuing feeds during transfusion affects outcomes. The study randomly assigns infants to one of two groups one where all enteral feeds are stopped for 4 hours before, during, and after packed red cell transfusion and another where feeding continues as usual throughout the transfusion period. Infants will remain on their assigned feeding strategy until reaching 34 weeks and 6 days gestational age. During feed withholding, hydration and blood sugar are maintained by parenteral nutrition or intravenous glucose according to local practice. Participants will be monitored from randomization until 40 weeks postmenstrual age for the development and severity of NEC, death, infections, nutritional support duration, growth, and other health outcomes. Researchers will track feeding practices, transfusions, and clinical events, with long-term follow-up until discharge from the hospital. The study intends to identify which feeding approach during transfusion might better prevent NEC in these vulnerable infants.
1-10 of 11
1